Clinical trials: Diffuse Large-Cell Lymphoma
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients…
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT06784167
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- OHSU Knight Cancer Institute
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop cancer cells from dividing so they stop growing…
- Conditions
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT00082784
- Testing
- Bortezomib, Alvocidib Hydrochloride, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or by presence of biomarkers associated with the…
- Trial name
- R-CHOP (NCT00450385)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- University of Miami
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer
RATIONALE: Telephone counseling by trained counselors may enhance the well-being and quality of life of patients who have undergone stem cell transplantation for cancer.
- Trial name
- NCT00049465
- Testing
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Where
- 9 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL)
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell…
- Conditions
- Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
- Trial name
- NCT07077512
- Testing
- Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor)
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to evaluate the safety, tolerability, and efficacy of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and…
- Trial name
- NCT05577364
- Testing
- Selinexor, R-CHOP Protocol
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Diffuse Large B-cell Lymphoma
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
- Trial name
- B-MIND (NCT02763319)
- Testing
- Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
- Where
- 158 sites in United States, Australia and 21 more
- Volunteers
- 453 people
- Sponsor
- Incyte Corporation
Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
This phase II trial is studying how well ixabepilone works in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT00058019
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
The First Affiliated Hospital of Nanchang University
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double…
- Trial name
- NCT05933967
- Testing
- Orelabrutinib+R-CHOP
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Shandong Cancer Hospital and Institute
Leukemia, Lymphoma
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005580
- Testing
- bryostatin 1, fludarabine phosphate
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Virginia Commonwealth University
Lymphoma
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's…
- Trial name
- NCT00003924
- Testing
- recombinant interferon alfa
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
Lymphoma, Non-Hodgkin Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas.
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
- Trial name
- NCT03223610
- Testing
- Venetoclax, Ibrutinib, Prednisone
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
- Trial name
- NCT01563861
- Testing
- RNA analysis, gene expression analysis, immunohistochemistry staining method
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
B-cell Lymphoma, Non Hodgkin Lymphoma
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
- Conditions
- B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma
- Trial name
- NCT03424603
- Testing
- STRO-001
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- Sutro Biopharma, Inc.
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large…
- Conditions
- Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Trial name
- NCT05600686
- Testing
- Cyclophosphamide, Doxorubicin, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
This phase 1 trial studies the side effects and the best dose of donor CD8+ memory T-cells in treating patients with hematolymphoid malignancies.
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Trial name
- NCT01523223
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Robert Lowsky
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.